Yüklüyor......
AHI-1 interacts with BCR-ABL and modulates BCR-ABL transforming activity and imatinib response of CML stem/progenitor cells
Chronic myeloid leukemia (CML) represents the first human malignancy successfully treated with a tyrosine kinase inhibitor (TKI; imatinib). However, early relapses and the emergence of imatinib-resistant disease are problematic. Evidence suggests that imatinib and other inhibitors may not effectivel...
Kaydedildi:
| Asıl Yazarlar: | , , , , , , , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
The Rockefeller University Press
2008
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2571939/ https://ncbi.nlm.nih.gov/pubmed/18936234 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1084/jem.20072316 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|